Professor Brendan McAdam:

The criteria have to change. What we are struggling with is the restrictive criteria that is not adopted by the European Society of Cardiology or in fact anybody else around the world. It is very restrictive and there is also the amount of precise paperwork we have to do. If you make any kind of error, you are kicked out and you cannot prescribe the medication, which is lifesaving for many patients. There is a new medicine coming on that is based on small interfering RNA therapy that you inject twice a year that really has a profound effect on your bad cholesterol, which has been shown to have a beneficial effect on cardiovascular outcomes in patients with established heart disease.